23.05.2016, 06:47
Results from Year Treatment of Repatha Presented for Diabetes Society
2016 News Releases | Astellas Pharma Inc.
OREANDA-NEWS. Amgen Astellas BioPharma K.K. and Astellas Pharma Inc. announced results from a one-year analysis of treatment with the cholesterol-lowering medication Repatha® Injection (generic name: Evolocumab (Genetically Recombination)) in Japanese hypercholesterolemia patients with Type 2 diabetes. These results were presented at the 59th Annual Meeting of the Japan Diabetes Society (JDS 2016) held in Kyoto on May 21.
The analysis demonstrated that in Japanese patients at high cardiovascular event risk with hypercholesterolemia on stable statin therapy, Repatha showed sustained efficacy and no concerning effects on glycemic control, regardless of baseline glycemic status.
Lead author Director Shizuya Yamashita, Rinku General Medical Center, and Professor of Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine said, “To help prevent cardiovascular events in diabetes patients, it is important to exercise comprehensive control over risk factors for hyperlipidemia and other arteriosclerotic diseases in addition to glycemic control. This time, we were able to confirm that the new LDLcholesterol-lowering medication Repatha demonstrated stable efficacy and safety for Japanese hypercholesterolemia patients with diabetes or who are at risk for diabetes. This knowledge is suggestive with regard to how therapy for diabetes patients whose LDL cholesterol level must be reduced more stringently should be provided in the future.”
The analysis demonstrated that in Japanese patients at high cardiovascular event risk with hypercholesterolemia on stable statin therapy, Repatha showed sustained efficacy and no concerning effects on glycemic control, regardless of baseline glycemic status.
Lead author Director Shizuya Yamashita, Rinku General Medical Center, and Professor of Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine said, “To help prevent cardiovascular events in diabetes patients, it is important to exercise comprehensive control over risk factors for hyperlipidemia and other arteriosclerotic diseases in addition to glycemic control. This time, we were able to confirm that the new LDLcholesterol-lowering medication Repatha demonstrated stable efficacy and safety for Japanese hypercholesterolemia patients with diabetes or who are at risk for diabetes. This knowledge is suggestive with regard to how therapy for diabetes patients whose LDL cholesterol level must be reduced more stringently should be provided in the future.”
Комментарии